Early tests of a Russian coronavirus vaccine showed encouraging results when details were published Friday, but experts said the trials were too small to prove safety and effectiveness.
In the Lancet study, Russian researchers reported on two small trials, each involving 38 healthy adults aged between 18 and 60, who were given a two-part immunisation.
Researchers underlined that larger and longer trials — including a placebo comparison — would be needed to establish the long-term safety and effectiveness of the vaccine for preventing Covid-19 infection. “Since vaccines are given to healthy people and, during the Covid-19 pandemic, potentially to everyone after approval following phase 3 trials, safety is paramount.”
President Vladimir Putin said in early August that the vaccine gave “sustainable immunity” and that one of his own daughters had been inoculated, even though Russia’s health ministry said clinical trials were not yet complete. It uses a cold-causing adenovirus, which is then modified and combined with a part of the new coronavirus, SARS-CoV-2.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Russia vaccine 'passes early trial test'
Read more »
Russia vaccine 'passes early trial test'Researchers underline that larger and longer trials – including a placebo comparison – would be needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.
Read more »
Russia vaccine 'passes early trial test'
Read more »
Russia vaccine 'passes early trial test'Researchers underline that larger and longer trials – including a placebo comparison – would be needed to establish the long-term safety and effectiveness of the vaccine for preventing COVID-19 infection.
Read more »
Widespread COVID-19 vaccination not likely available until mid-2021, World Health Organization saysThere are currently 34 vaccines globally carrying out human trials, according to WHO, with 142 vaccine candidates currently in the pre-clinical trial phase
Read more »
Novavax coronavirus vaccine is safe, published results showEarly stage clinical trial results show the Covid-19 vaccine candidate made by Novavax is safe and elicits an immune response, according to a study published in The New England Journal of Medicine.
Read more »